Infusion Reactions to Infliximab in Pediatric Patients with Inflammatory Bowel Disease
Infliximab (IFX) is a recombinant DNA-derived chimeric IgG monoclonal antibody protein that inhibits tumor necrosis factor alpha (TNF-α). IFX, like other agents derived from foreign proteins, can cause infusion reactions both during and after the infusion. The incidence of infusion reactions ranges...
Saved in:
| Main Authors: | Rajmohan Dharmaraj, Tess Pei Lemon, Rasha Elmaoued, Ricardo Orlando Castillo, Razan Alkhouri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Children |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9067/11/11/1366 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
INFLIXIMAB IN TREATMENT OF ACTIVE JUVENILE ARTHRITIS
by: E. S. Zholobova, et al.
Published: (2012-05-01) -
Metabolic Bone Disease in Pediatric Patients with Short Bowel Syndrome
by: Hannah DeGonza, et al.
Published: (2025-02-01) -
A case of severe allergic reaction following multiple intravenous infusion treatments
by: XU Feng, ZHANG Li, ZHANG Hongting, SHI Chuqi, JIA Qiaoru, XIAO Hao, MENG Juan
Published: (2024-10-01) -
Knowledge, attitude, and practice toward azithromycin infusion reactions among pediatric nurses: a cross-sectional study
by: Linlin Wei, et al.
Published: (2025-08-01) -
Safety of Accelerated Rituximab Infusion in Rheumatic Diseases: A Systematic Review
by: Jozélio Freire de Carvalho, et al.
Published: (2025-06-01)